Conversation

Notices

1. Ars Technica (arstechnica@mastodon.social)'s status on Wednesday, 20-Nov-2024 02:11:55 JST Ars Technica

   Novo Nordisk sells hit weight-loss drug in China—at fraction of US price
   As US struggles to afford GLP-1 drugs, the rest of the world sees much lower prices.
   https://arstechnica.com/health/2024/11/novo-nordisk-sells-hit-weight-loss-drug-in-china-at-fraction-of-us-price/?utm_brand=arstechnica&utm_social-type=owned&utm_source=mastodon&utm_medium=social

   • HBX (hbxc0re@mastodon.social)'s status on Wednesday, 20-Nov-2024 07:18:53 JST HBX

     in reply to

     @arstechnica US Pharma has been strong arming US citizens to front the bill for other countries for decades, whats new....And lets not get started with the insurance companies...ShitholeUSA.